News | Prostate Cancer | March 27, 2018

Study finds metastatic cancer rates and cancer mortality rates drop significantly when brachytherapy combined with external beam radiation therapy

Combination Radiotherapy Beneficial in Treating Prostate Cancer

March 27, 2018 — While there are many treatment options for men with prostate cancer, a recent national study published in the Journal of the American Medical Association compared the effectiveness of treatments for high-risk prostate cancer.

Said Daniel Krauss, M.D., radiation oncologist and principal investigator at the Beaumont, Royal Oak research site, “Though retrospective, more than 1,800 very high-risk patients were relatively equally divided into treatment groups – primary surgery; external beam radiotherapy; and external beam with internal radiation (brachytherapy). Compared to other approaches, the combination of external beam and brachytherapy showed dramatic improvements in cancer mortality and metastatic disease rates – something radiation oncologists at Beaumont have suspected for some time.”

Researchers found treating patients with a combination of external beam with brachytherapy resulted in a decline in metastatic cancer rates from 25 to 8 percent. Metastatic cancer is cancer that has spread to a body site remote from where it started. Cancer mortality rates decreased from 12 percent in patients treated with primary surgery or external radiation alone, to 3 percent in patients treated with the combination of external radiation plus brachytherapy.

Brachytherapy is a form of radiation therapy that involves placing a radioactive source within the patient’s body at the site of the cancer. The radioactive source used to destroy the cancer is delivered by devices called implants.

Brachytherapy may be performed in combination with external beam radiation therapy to help destroy the main mass of tumor cells for certain types of cancer.

Krauss is a leading expert in treating prostate cancer with high-dose-rate brachytherapy. Depending on the type of prostate cancer, some patients can be treated entirely with two, or sometimes as little as one, minimally invasive brachytherapy treatment. He continues his research to further refine the treatment duration and establish an optimal treatment dose.

For more information: www.jamanetwork.com

Reference

Kishan A.U., Cook R.R., Ciezki J.P., et al. "Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer." Journal of the American Medical Association, March 6, 2018. doi:10.1001/jama.2018.0587

 


Related Content

News | Contrast Agents

April 23, 2026 — On April 23, GE HealthCare announced the first patient has been dosed in the international, multi ...

Time April 23, 2026
arrow
News | Radiology Business

April 10, 2026 — The radiation therapy team at The Ohio State University Wexner Medical Center, The James Cancer ...

Time April 10, 2026
arrow
News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News | FDA

March 20, 2026 — Siemens Healthineers recently announced its Varian TrueBeam radiotherapy systems, which include ...

Time March 24, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
Subscribe Now